SOP Guide for Pharma

Analytical Method Development: SOP for Analytical Method for Creams and Gels – V 2.0

Analytical Method Development: SOP for Analytical Method for Creams and Gels – V 2.0

Standard Operating Procedure for Analytical Method Development for Cream and Gel Formulations


Department Analytical Method Development
SOP No. SOP/AMD/165/2025
Supersedes SOP/AMD/165/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

To define the procedure for developing and validating analytical methods for pharmaceutical creams and gels, including assay, content uniformity, viscosity, pH, drug release, and physical

stability to ensure product quality and regulatory compliance.

2. Scope

This SOP is applicable to the Analytical Method Development (AMD) department for semi-solid dosage forms such as creams and gels intended for topical or transdermal delivery, including ANDA/NDA submission batches and commercial scale-up formulations.

3. Responsibilities

  • Analytical Scientist: Develops analytical methods based on formulation composition and tests them for specificity, accuracy, and reproducibility.
  • Formulation Scientist: Shares formulation attributes, target strength, and performance expectations.
  • QA Officer: Ensures adherence to GMP, reviews method validation reports, and oversees compliance documentation.
  • Head – AMD: Provides final approval for validated methods and ensures method transfer readiness.

4. Accountability

The Head of Analytical Method Development is accountable for the scientific justification, validation compliance, and documentation accuracy of all methods developed for cream and gel formulations.

5. Procedure

5.1 Understanding Formulation Matrix

  1. Obtain details of the active ingredient (API) solubility, excipients used (gelling agents, emollients, surfactants), and intended dosage form (cream or gel).
  2. Classify the formulation as oil-in-water (O/W) cream, water-in-oil (W/O) cream, or hydrogel for method optimization.

5.2 Assay and Content Uniformity

  1. Accurately weigh the sample and dilute with a suitable solvent (e.g., ethanol, methanol).
  2. If insoluble components are present, centrifuge or filter the sample before analysis.
  3. Analyze using validated HPLC or UV spectrophotometry.
  4. Acceptance Criteria: 95.0%–105.0% of label claim with %RSD ≤ 2.0% for multiple samples.
  5. Log data in Annexure-1: Assay Log Sheet.

5.3 Viscosity Measurement

  1. Use a Brookfield viscometer with suitable spindle (e.g., LV-3, LV-4) depending on viscosity range.
  2. Maintain sample at 25 ± 2°C during testing.
  3. Record values at multiple RPMs and calculate average viscosity.
  4. Document in Annexure-2: Viscosity Data Sheet.

5.4 pH Determination

  1. Disperse approximately 1 g of cream/gel in 10 mL of distilled water and mix thoroughly.
  2. Measure pH using a calibrated pH meter at room temperature.
  3. Acceptance: pH 4.0–7.5 depending on formulation type.

5.5 In-Vitro Release Testing (IVRT)

  1. Use Franz diffusion cells with synthetic membranes (e.g., cellulose acetate or Strat-M).
  2. Apply ~300 mg of sample in the donor compartment and use receptor medium (e.g., PBS pH 7.4) in the receptor chamber.
  3. Maintain temperature at 32 ± 1°C and stir continuously.
  4. Withdraw receptor samples at 1, 2, 4, 6, and 8 hours; analyze via HPLC.
  5. Plot cumulative drug release and determine release rate (µg/cm²/h).
  6. Log in Annexure-3: IVRT Profile Sheet.

5.6 Physical and Chemical Stability

  1. Store samples at 25°C/60% RH and 40°C/75% RH.
  2. Evaluate at Day 0, 15, 30, 60, 90 for:
    • Color, odor, phase separation
    • Assay and pH
    • Drug release performance
  3. Document in Annexure-4: Stability Monitoring Log.

5.7 Method Validation

  1. Validate assay and IVRT methods as per ICH Q2(R2):
  2. Parameters:
    • Specificity
    • Linearity (R² ≥ 0.999)
    • Accuracy (98%–102%)
    • Precision (%RSD ≤ 2%)
    • Robustness
  3. Summarize in Annexure-5: Method Validation Report.

6. Abbreviations

  • IVRT: In-Vitro Release Testing
  • HPLC: High Performance Liquid Chromatography
  • RSD: Relative Standard Deviation
  • RH: Relative Humidity
  • SOP: Standard Operating Procedure

7. Documents

  1. Assay Log Sheet – Annexure-1
  2. Viscosity Data Sheet – Annexure-2
  3. IVRT Profile Sheet – Annexure-3
  4. Stability Monitoring Log – Annexure-4
  5. Method Validation Report – Annexure-5

8. References

  • ICH Q2(R2) – Validation of Analytical Procedures
  • FDA Guidance on Topical Product Performance Testing
  • USP <1724> – Semisolid Drug Products
  • WHO Guidelines on Stability Testing of Pharmaceutical Products

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Assay Log Sheet

Sample ID Assay (%) % RSD Analyst
CRG/2025/017 99.3% 1.4% Sunita Reddy

Annexure-2: Viscosity Data Sheet

Sample ID Spindle RPM Viscosity (cP) Analyst
GEL/2025/004 LV-3 30 3500 Rajesh Kumar

Annexure-3: IVRT Profile Sheet

Time (hr) Drug Released (µg/cm²) Analyst
1 15.2 Ajay Verma
2 28.5 Ajay Verma
4 52.9 Ajay Verma

Annexure-4: Stability Monitoring Log

Time Point Condition Observation Analyst
30 Days 40°C/75% RH No change in color or phase Sunita Reddy

Annexure-5: Method Validation Report

Parameter Result Acceptance Status
Linearity R² = 0.9994 ≥ 0.999 Pass
Accuracy 98.7%–101.4% 98%–102% Pass

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Included IVRT and validation annexures Annual SOP Review
Exit mobile version